Cargando…
PET/MR for therapy response evaluation in malignant lymphoma: initial experience
OBJECT: To evaluate the feasibility of positron emission tomography/magnetic resonance imaging (PET/MR) with (18)fluoro-2-deoxyglucose (FDG) for therapy response evaluation of malignant lymphoma. MATERIALS AND METHODS: Nine patients with malignant lymphoma who underwent FDG-PET/MR before and after c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572376/ https://www.ncbi.nlm.nih.gov/pubmed/22983794 http://dx.doi.org/10.1007/s10334-012-0342-7 |
_version_ | 1782259312112959488 |
---|---|
author | Platzek, Ivan Beuthien-Baumann, Bettina Langner, Jens Popp, Manuel Schramm, Georg Ordemann, Rainer Laniado, Michael Kotzerke, Jörg van den Hoff, Jörg |
author_facet | Platzek, Ivan Beuthien-Baumann, Bettina Langner, Jens Popp, Manuel Schramm, Georg Ordemann, Rainer Laniado, Michael Kotzerke, Jörg van den Hoff, Jörg |
author_sort | Platzek, Ivan |
collection | PubMed |
description | OBJECT: To evaluate the feasibility of positron emission tomography/magnetic resonance imaging (PET/MR) with (18)fluoro-2-deoxyglucose (FDG) for therapy response evaluation of malignant lymphoma. MATERIALS AND METHODS: Nine patients with malignant lymphoma who underwent FDG-PET/MR before and after chemotherapy were included in this retrospective study. Average time between the two scans was 70 days. The scans were evaluated independently by two nuclear medicine physicians. The Ann Arbor classification was used to describe lymphoma stage. Furthermore, the readers also rated PET image quality using a five point scale. Weighted kappa (κ) was used to calculate interrater agreement. RESULTS: The initial scan showed foci of increased FDG uptake in all patients, with Ann Arbor stage varying between I and IV. In the follow-up examination, all but one patient showed complete response to chemotherapy. PET image quality was rated as very good or excellent for all scans. Interrater agreement was excellent regarding Ann Arbor stage (κ = 0.97) and good regarding image quality (κ = 0.41). CONCLUSION: PET/MR shows promising initial results for therapy response evaluation in lymphoma patients. |
format | Online Article Text |
id | pubmed-3572376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-35723762013-02-21 PET/MR for therapy response evaluation in malignant lymphoma: initial experience Platzek, Ivan Beuthien-Baumann, Bettina Langner, Jens Popp, Manuel Schramm, Georg Ordemann, Rainer Laniado, Michael Kotzerke, Jörg van den Hoff, Jörg MAGMA Research Article OBJECT: To evaluate the feasibility of positron emission tomography/magnetic resonance imaging (PET/MR) with (18)fluoro-2-deoxyglucose (FDG) for therapy response evaluation of malignant lymphoma. MATERIALS AND METHODS: Nine patients with malignant lymphoma who underwent FDG-PET/MR before and after chemotherapy were included in this retrospective study. Average time between the two scans was 70 days. The scans were evaluated independently by two nuclear medicine physicians. The Ann Arbor classification was used to describe lymphoma stage. Furthermore, the readers also rated PET image quality using a five point scale. Weighted kappa (κ) was used to calculate interrater agreement. RESULTS: The initial scan showed foci of increased FDG uptake in all patients, with Ann Arbor stage varying between I and IV. In the follow-up examination, all but one patient showed complete response to chemotherapy. PET image quality was rated as very good or excellent for all scans. Interrater agreement was excellent regarding Ann Arbor stage (κ = 0.97) and good regarding image quality (κ = 0.41). CONCLUSION: PET/MR shows promising initial results for therapy response evaluation in lymphoma patients. Springer-Verlag 2012-09-16 2013 /pmc/articles/PMC3572376/ /pubmed/22983794 http://dx.doi.org/10.1007/s10334-012-0342-7 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Research Article Platzek, Ivan Beuthien-Baumann, Bettina Langner, Jens Popp, Manuel Schramm, Georg Ordemann, Rainer Laniado, Michael Kotzerke, Jörg van den Hoff, Jörg PET/MR for therapy response evaluation in malignant lymphoma: initial experience |
title | PET/MR for therapy response evaluation in malignant lymphoma: initial experience |
title_full | PET/MR for therapy response evaluation in malignant lymphoma: initial experience |
title_fullStr | PET/MR for therapy response evaluation in malignant lymphoma: initial experience |
title_full_unstemmed | PET/MR for therapy response evaluation in malignant lymphoma: initial experience |
title_short | PET/MR for therapy response evaluation in malignant lymphoma: initial experience |
title_sort | pet/mr for therapy response evaluation in malignant lymphoma: initial experience |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572376/ https://www.ncbi.nlm.nih.gov/pubmed/22983794 http://dx.doi.org/10.1007/s10334-012-0342-7 |
work_keys_str_mv | AT platzekivan petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT beuthienbaumannbettina petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT langnerjens petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT poppmanuel petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT schrammgeorg petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT ordemannrainer petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT laniadomichael petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT kotzerkejorg petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience AT vandenhoffjorg petmrfortherapyresponseevaluationinmalignantlymphomainitialexperience |